MyFinsight
Home
Blog
About
Proceeds from redemption
of investments
$5,000,000
(12.29%↑ Y/Y)
Net cash provided by
investing activities
$4,017,793
(-9.77%↓ Y/Y)
Canceled cashflow
$982,207
Net change in cash
and cash...
$721,083
(136.89%↑ Y/Y)
Canceled cashflow
$3,296,710
Purchase of investments
$982,207
Increase in accounts
payable and accrued...
$1,267,132
(709.32%↑ Y/Y)
Stock based
compensation
$532,951
(-21.84%↓ Y/Y)
Decrease in prepaid
expenses and other assets
-$455,110
(5.22%↑ Y/Y)
Amortization of intangibles
$25,000
(-50.00%↓ Y/Y)
Net cash used in
operating activities
-$3,144,340
(49.93%↑ Y/Y)
Net cash used in
financing activities
-$151,947
(-19.60%↓ Y/Y)
Effect of foreign
exchange rate on changes...
-$423
Canceled cashflow
$2,280,193
Net loss
-$5,371,042
(28.46%↑ Y/Y)
Payment of amounts due to
officers
$150,000
(-50.00%↓ Y/Y)
Proceeds from exercise of
warrants, net
-$1,947
Realized and unrealized
gain and accrued...
$53,491
(-62.06%↓ Y/Y)
Back
Back
Cash Flow
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)
source: myfinsight.com